Aerovate Therapeutics, Inc. (AVTE) NASDAQ
2.68
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aerovate Therapeutics, Inc.
Address
930 Winter Street
Waltham, MA 02116
United States of America (the)
Phone
617 443 2400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 30, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Timothy Noyes | Chief Executive Officer & Director | 936,899 | 1962 |
| Ralph W. Niven M.R Pharm.S | Chief Scientific Officer | 372,333 | 1960 |
| Benjamin T. Dake | Founder, President, Chief Operating Officer & Secretary | 435,500 | 1976 |
| Hunter Gillies | Chief Medical Officer | 512,742 | 1966 |
| George A. Eldridge | Chief Financial Officer & Treasurer | 658,600 | 1963 |
| Sanjeev Khindri | Executive Vice President of Clinical Development | 0 | N/A |
| Stephen Yu | Senior Vice President of Quality | 0 | N/A |
| Donna Dea | Head of Regulatory Affairs | 0 | N/A |
| Susan Fischer | Executive Vice President of Development Operations | 0 | N/A |
| Cheryl Lassen | Senior Vice President of Clinical Development | 0 | N/A |
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
